文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

不同剂量阿托伐他汀、瑞舒伐他汀和辛伐他汀对低密度脂蛋白胆固醇反应的变异性:VOYAGER 研究结果。

Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.

机构信息

AstraZeneca Gothenburg, Pepparedsleden 1, Mölndal SE-431 83, Sweden Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-413 45, Sweden

Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg SE-413 45, Sweden.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):212-7. doi: 10.1093/ehjcvp/pvw006. Epub 2016 Mar 29.


DOI:10.1093/ehjcvp/pvw006
PMID:27533947
Abstract

AIMS: Patient response to statin treatment is individual and varied. As a consequence, when using a specific-dose approach, as recommended in the 2013 American College of Cardiology/American Heart Association guideline, there will be a range of reductions in the concentration of low-density lipoprotein cholesterol (LDL-C). The aim of this study was to use individual patient data from the VOYAGER meta-analysis to determine the extent of the variability in LDL-C reduction in response to treatment across the recommended doses of different statins. METHODS AND RESULTS: The percentage change from baseline in LDL-C was calculated using individual subject data collected from 32 258 patients treated with atorvastatin 10-80 mg, rosuvastatin 5-40 mg, or simvastatin 10-80 mg. The percentage change in LDL-C for each patient was then used to generate waterfall plots that demonstrated the extent of the variability in response to treatment at all doses of the three statins. The standard deviation of LDL-C reduction for all statins and doses ranged from 12.8 to 17.9%. The percentage of patients experiencing a suboptimal response (<30% reduction in LDL-C) ranged from 5.3 to 53.3%. CONCLUSION: These results indicate that there is considerable individual variation in the LDL-C reduction at all doses of simvastatin, atorvastatin, and rosuvastatin.

摘要

目的:患者对他汀类药物治疗的反应是个体差异的。因此,当使用特定剂量方法时,如 2013 年美国心脏病学会/美国心脏协会指南所推荐的那样,低密度脂蛋白胆固醇(LDL-C)的浓度会有一系列降低。本研究的目的是利用 VOYAGER 荟萃分析的个体患者数据,确定在推荐剂量范围内,不同他汀类药物治疗的 LDL-C 降低的变异性程度。

方法和结果:使用阿托伐他汀 10-80mg、瑞舒伐他汀 5-40mg 或辛伐他汀 10-80mg 治疗的 32258 例患者的个体受试者数据计算 LDL-C 从基线的百分比变化。然后,使用每个患者的 LDL-C 百分比变化生成瀑布图,以显示三种他汀类药物在所有剂量下治疗反应的变异性程度。所有他汀类药物和剂量的 LDL-C 降低的标准差范围为 12.8%至 17.9%。经历非最佳反应(LDL-C 降低<30%)的患者比例范围为 5.3%至 53.3%。

结论:这些结果表明,辛伐他汀、阿托伐他汀和瑞舒伐他汀在所有剂量下的 LDL-C 降低都存在相当大的个体差异。

相似文献

[1]
Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER.

Eur Heart J Cardiovasc Pharmacother. 2016-3-29

[2]
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.

Atherosclerosis. 2015-6-3

[3]
Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis.

Eur J Prev Cardiol. 2016-5

[4]
A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.

Am J Cardiol. 2016-5-1

[5]
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Clin Ther. 2004-9

[6]
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.

Am J Geriatr Pharmacother. 2007-9

[7]
A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.

J Womens Health (Larchmt). 2016-1

[8]
Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia.

Lipids Health Dis. 2015-9-13

[9]
Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.

J Formos Med Assoc. 2002-7

[10]
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.

Atherosclerosis. 2013-3-4

引用本文的文献

[1]
Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial.

Trials. 2025-9-1

[2]
Cardiovascular Outcomes and Variability in Plasma Lipid Levels Across Body Mass Index Categories: The ARIC Study.

J Nutr Metab. 2025-7-16

[3]
Real-World Assessment of the Association Between PCSK9i Adherence and LDL Reduction and Variability in a Chinese Clinical Practice.

Clin Epidemiol. 2025-6-9

[4]
Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants.

Drug Saf. 2025-4-26

[5]
Low-Density Lipoprotein Cholesterol Increases Significantly During Brief Discontinuation of Atorvastatin and Correlates With Metabolite Half-Lives.

Pharmacol Res Perspect. 2025-4

[6]
Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region.

J Clin Med. 2025-3-9

[7]
Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment.

Eur Heart J Cardiovasc Pharmacother. 2025-7-7

[8]
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy.

Drugs. 2025-1

[9]
A gut feeling of statin.

Gut Microbes. 2024

[10]
Amelioration of gait and balance disorders by rosuvastatin is associated with changes in cerebrovascular reactivity in older patients with hypertensive treatment.

Hypertens Res. 2024-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索